ResMed logo-fullcolor.jpg
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
10 juin 2024 09h05 HE | ResMed Inc.
ResMed-supported research presented at SLEEP2024 demonstrates the effectiveness and value of positive airway pressure (PAP) treatment for OSA.
ResMed logo-fullcolor.jpg
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
23 mai 2024 09h05 HE | ResMed Inc.
New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
ResMed logo-fullcolor.jpg
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
16 mai 2024 16h35 HE | ResMed Inc.
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
ResMed logo-fullcolor.jpg
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
06 mars 2024 09h05 HE | ResMed Inc.
ResMed unveils the AirFit F40, an ultra-compact full-face CPAP mask offering the comfort of smaller masks without sacrificing performance.